Bora CDMO Bora CDMO

X

Find the latest Drugs in Development and Pipeline Prospector News of ConSynance Therapeutics.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
ConSynance Therapeutics
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
Health Sciences Campus 11 University Place Rensselaer, NY 12144
Telephone
Telephone
+1 (518) 275-0176
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

CSTI-500 is a first-in-class, orally administered new chemical entity and an optimally balanced Triple Monoamine Reuptake inhibitor (TRI). It is being investigated for the treatment for prader-willi syndrome.


Lead Product(s): CSTI-500

Therapeutic Area: Genetic Disease Product Name: CSTI-500

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 30, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY